ZYZhi Bin Ye

Zhi Bin Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhi Bin Ye has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Hui Min Jin

    Shanghai Dong Ji Fresenius Hemodialysis Center, Shanghai, China; Department of Nephrology, the People's Hospital of Wenshan Prefecture, Yunnan Province, China

    7 shared publications
  • Yao Liu

    Department of Nephrology, Huadong Hospital, Fudan University

    7 shared publications
  • Xiu Hong Yang

    Department of Nephrology, Huadong Hospital, Fudan University

    6 shared publications
  • Chen Sheng Fu

    Department of Nephrology, Huadong Hospital, Fudan University

    5 shared publications
  • Chensheng Fu

    Department of Nephrology, Huadong Hospital, Fudan University, Shanghai, China

    4 shared publications
  • Yi Jun Lu

    Department of Nephrology, Huadong Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital, Fudan University, Shanghai, China

    4 shared publications

Latest Publications

  • Open Access

    Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence

    by Xiu Hong Yang, Yao Liu, Chen Sheng Fu, Hui Min Jin, Zhi Bin Ye

    Introduction: Diabetic kidney disease (DKD) remains a leading cause of end-stage kidney disease despite advances with renin–angiotensin system blockade, sodium–glucose cotransporter 2 inhibitors, finerenone, and glucagon-like peptide-1 receptor agonists. Therapeutic monoclonal antibodies may offer a targeted strategy to modulate inflammatory, fibrotic, metabolic, and vascular pathways involved in DKD. This review summarizes the mechanistic rationale, clinical evidence, translational barriers, and future prospects of antibody-based therapies for DKD. Methods: We conducted a narrative literature review using PubMed, the Cochrane Library, and ClinicalTrials.gov from database inception to March 31, 2026. We prioritized peer-reviewed preclinical studies, clinical trials, and high-quality reviews addressing mAb-based strategies targeting DKD-related pathways, including TGF-β1, VEGF-B, CTGF, suPAR, integrin αvβ8, signal regulatory protein α, and PCSK9. Results: Phase II studies of anti-TGF-β1 and anti-VEGF-B antibodies failed to show meaningful renal benefit, highlighting challenges such as pathway redundancy, delayed intervention, insufficient intrarenal target engagement, and off-kidney toxicity. Anti-CTGF therapy showed an early signal of albuminuria, whereas anti-suPAR remains under clinical evaluation. Emerging preclinical targets, including integrin αvβ8 and signal regulatory protein α, may provide more kidney-focused modulation of fibrotic and inflammatory pathways. PCSK9 monoclonal antibodies, particularly evolocumab and alirocumab, appear promising because they may confer renal benefit through lipid lowering and kidney-intrinsic effects on lipotoxicity, oxidative stress, AMPK signaling, and profibrotic pathways. Conclusion: Monoclonal antibodies represent a biologically compelling but clinically underdeveloped strategy for DKD. Future progress will require earlier biomarker-informed patient selection, confirmation of intrarenal target engagement, appropriate renal endpoints, and rational combination with established kidney-protective therapies.

  • Open Access

    Normal serum uric acid gout: a neglected and challenging condition

    by Xiu Hong Yang, Xiao Li Zhan, Qing Xia Xuan, Hui Min Jin, Zhi Bin Ye

    During acute gout flares, serum uric acid (SUA) levels may remain within the normal range, making diagnosis based solely on SUA unreliable. A systematic evaluation incorporating clinical symptoms and imaging (ultrasound, dual-source CT) is essential to detect monosodium urate (MSU) crystal deposition. Normal-SUA gout often presents with more pronounced inflammation, fever, elevated white blood cell count and C-reactive protein, and may occur after surgery or hemodialysis. Tophi can appear at typical or atypical sites (e.g., face, neck). No specific treatment guidelines exist, but lowering SUA to <360 μmol/L (6 mg/dl) reduces gout flares and promotes MSU dissolution. Emerging therapies—including anti-IL-1β monoclonal antibodies, NLRP3 inhibitors, uricases, and green tea components—show promise in controlling attacks and dissolving crystals without affecting SUA levels.

  • Open Access

    Urine albumin-to-creatinine ratio and risks of incident arterial thromboembolism and pulmonary embolism among adults—a prospective cohort study

    by Xiu Hong Yang, Yao Liu, Zhen Xing Zhang, Yi Jun Lu, Chen Sheng Fu, Hui Min Jin, Zhi Bin Ye, Xiao Li Zhang

  • Reply to “Daytime napping and risk of incident main adverse cardiovascular events and mortality among adults with type 2 diabetes”

    by Xiu Hong Yang, Yao Liu, Xin Xin Jiang, Zhen Xing Zhang, Yi Jun Lu, Chen Sheng Fu, Hui Min Jin, Zhi Bin Ye

  • Daytime napping and risk of incident main adverse cardiovascular events and mortality among adults with type 2 diabetes

    by Xiu Hong Yang, Yao Liu, Xin Xin Jiang, Zhen Xing Zhang, Yi Jun Lu, Chen Sheng Fu, Hui Min Jin, Zhi Bin Ye


  • Open Access

    Association of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: a comprehensive meta-analysis

    by Yao Liu, Zhen Xing Zhang, Chen Sheng Fu, Zhi Bin Ye, Hui Min Jin, Xiu Hong Yang

    This meta-analysis aims to investigate the impact of abnormalities in mineral metabolic markers, including serum phosphate and calcium, intact parathyroid hormone (iPTH), and fibroblast growth factor 23 (FGF23) on the risk of fractures in patients with chronic kidney disease (CKD). A systematic search was conducted across MEDLINE, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register for Controlled Trials. The outcomes were association of mineral metabolic markers with the risk of fractures in patients with chronic kidney disease. Pooled risk estimates and 95% confidence intervals (CIs) were calculated using fixed-effects or random-effects models. Thirty-two studies were included in the meta-analysis. High and low levels of serum phosphate in hemodialysis (HD) patients were both associated with an increased risk of fractures (RR = 1.08, 95% CI 1.02–1.15, P = 0.013; RR = 1.13, 95% CI 1.02–1.25, P = 0.022, respectively). Similarly, abnormal levels of iPTH in CKD patients, both high and low, were associated with increased fracture risk (RR = 1.25, 95% CI 1.20–1.31, P < 0.001; RR = 1.41, 95% CI 1.10–1.82, P = 0.007, respectively). Elevated FGF23 levels were also linked to an increased risk of fractures (RR = 1.32, 95% CI 1.06–1.66, P = 0.015). While a higher level of calcium exhibited a trend towards reduced fracture incidence without statistical significance (RR = 0.90, 95% CI 0.77–1.05, P = 0.181), lower calcium levels tended to increase fracture risk without statistical significance (RR = 1.11, 95% CI 0.99–1.24, P = 0.087). Notably, subjects treated with calcium and phosphorus modulating drugs demonstrated a statistically significant reduction in fractures among CKD patients undergoing dialysis (phosphate binders, RR = 0.79, 95% CI 0.70–0.89; cinacalcet, RR = 0.74, 95% CI 0.59–0.93; vitamin D analogues, RR = 0.82, 95% CI 0.74–0.92, respectively). This meta-analysis underscores the association between abnormal mineral metabolic markers, including high serum phosphate, iPTH, and FGF23, and an increased risk of fractures in CKD patients. Notably, both elevated and decreased levels of phosphate and iPTH contribute to fracture risk. The efficacy of active vitamin D, phosphorus binders, and cinacalcet in preventing fractures was observed in HD patients but not in the non-dialysis CKD population. PROSPERO CRD42023493951.


  • Open Access

    Sleep traits and risk of end-stage renal disease: a mendelian randomization study

    by Kaixin Li, Jiaxi Zhao, Wenjing Yang, Zhibin Ye

    Background: Epidemiological evidence relating sleep disorders to end-stage renal disease (ESRD) has been obscure. The present study is sought to examine the association between sleep traits and ESRD.Methods: For this analysis, we selected genetic instruments for sleep traits from published genome-wide association studies (GWAS). As instrumental variables, independent genetic variations linked with seven sleep-related features (sleep duration, getting up in the morning, daytime napping, chronotype of morning/evening person, sleeplessness/insomnia, non-snoring, and daytime dozing) were chosen. A two-sample Mendelian randomization (TSMR) study was conducted to assess the causal relationship between sleep traits and ESRD (N = 33,061). The reverse MR analysis subsequently determined the causal relationship between ESRD and sleep traits. The causal effects were estimated using inverse variance weighted, MR-Egger, weighted median. To conduct sensitivity studies, Cochran’s Q test, MR-Egger intercept test, MR-PRESSO, leave-one-out analysis, and funnel plot were used. To study the potential mediators, multivariable mendelian randomization analyses were undertaken further.Results: Genetically predicted sleeplessness/ insomnia (OR = 6.11, 95%CI 1.00-37.3, P = 0.049, FDR = 0.105), getting up in the morning easily(OR = 0.23, 95%CI 0.063–0.85; P = 0.0278, FDR = 0.105), non-snoring (OR = 4.76E-02, 95%CI 2.29E-03-0.985, P = 0.0488, FDR = 0.105) was suggestively associated with the risk of ESRD. However, we found no evidence favoring a causal association between other sleep traits and ESRD through the IVW method.Conclusion: The present TSMR found no strong evidence of a bidirectional causal association between genetically predicted sleep traits and ESRD.


  • Open Access

    Atorvastatin promotes bone formation in aged apoE–/– mice through the Sirt1–Runx2 axis

    by Wei Hong, Zhanying Wei, Zhaohui Qiu, Zheng Li, Chensheng Fu, Zhibin Ye, Xiaoya Xu

    Background: Statins are the most widely used drugs in elderly patients; the most common clinical application of statins is in aged hyperlipemia patients. There are few studies on the effects and mechanisms of statins on bone in elderly mice with hyperlipemia. The study is to examine the effects of atorvastatin on bone phenotypes and metabolism in aged apolipoprotein E-deficient (apoE–/–) mice, and the possible mechanisms involved in these changes.Methods: Twenty-four 60-week-old apoE–/–mice were randomly allocated to two groups. Twelve mice were orally gavaged with atorvastatin (10 mg/kg body weight/day) for 12 weeks; the others served as the control group. Bone mass and skeletal microarchitecture were determined using micro-CT. Bone metabolism was assessed by serum analyses, qRT-PCR, and Western blot. Bone marrow-derived mesenchymal stem cells (BMSCs) from apoE–/–mice were differentiated into osteoblasts and treated with atorvastatin and silent information regulator 1 (Sirt1) inhibitor EX-527.Results: The results showed that long-term administration of atorvastatin increases bone mass and improves bone microarchitecture in trabecular bone but not in cortical bone. Furthermore, the serum bone formation marker osteocalcin (OCN) was ameliorated by atorvastatin, whereas the bone resorption marker tartrate-resistant acid phosphatase 5b (Trap5b) did not appear obviously changes after the treatment of atorvastatin. The mRNA expression of Sirt1, runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), and OCN in bone tissue were increased after atorvastatin administration. Western blot showed same trend in Sirt1 and Runx2. The in vitro study showed that when BMSCs from apoE–/–mice were pretreated with EX527, the higher expression of Runx2, ALP, and OCN activated by atorvastatin decreased significantly or showed no difference compared with the control. The protein expression of Runx2 showed same trend.Conclusions: Accordingly, the current study validates the hypothesis that atorvastatin can increase bone mass and promote osteogenesis in aged apoE−/−mice by regulating the Sirt1–Runx2 axis.